|
![]() |
|||
|
||||
OverviewFull Product DetailsAuthor: Eric H. BernickerPublisher: Springer International Publishing AG Imprint: Springer International Publishing AG Edition: 1st ed. 2023 Weight: 0.732kg ISBN: 9783031337499ISBN 10: 3031337492 Pages: 321 Publication Date: 31 August 2023 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of ContentsSection 1: Biology Exposures and cancer: historical concerns Molecular mechanisms of environmental oncogenesis Air pollution and lung cancer Radiation exposure and cancer ( Chernobyl) Lost opportunities: deforestation , sick oceans and fewer drugs from nature Section 2 :Food , Lifestyle and Cancer Meat consumption. dietary choice and cancer Alcohol and cancer Tobacco, second-hand smoke and cancer The environmental cost of factory farming and cancer Sun exposure and skin cancer Section 3: Industry and Cancer Petrochemical plants and cancer Pesticides and cancer Environmental justice, equity and cancer Asbestos, mining, mesothelioma and lung cancer Legal issues in cancer and pollution Section 4: War and Cancer Agent orange and cancer Nuclear weapons and cancer Postscript: The role of the physician as activist?ReviewsAuthor InformationEric H. Bernicker MD Neal Cancer Center, Houston Methodist Hospital Houston, TX, USA Dr. Bernicker earned his medical degree from Baylor College of Medicine in Houston, TX in 1990. Subsequently, he completed his residency at Baylor Affiliated Hospitals and was chief medical resident at Ben Taub General Hospital from 1993–1994. Dr. Bernicker held a faculty appointment at Baylor College of Medicine as a clinical assistant professor from 1996–2012 before joining the Houston Methodist Cancer Center in January 2013, where he serves as director of Medical Thoracic Oncology. As a physician-scientist, Dr. Bernicker oversees the expansion of clinical trials at The Methodist Hospital relating to Thoracic Oncology with all stages of disease, a combination of cooperative trials, industry trials of novel targeted agents and investigator initiated trials looking at reversing immunotherapy resistance. Tab Content 6Author Website:Countries AvailableAll regions |